This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.00310-08v1 52/7/2639    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Google Scholar Articles by Critchley, I. A. Articles by Janjic, N. PubMed PubMed Citation Articles by Critchley, I. A. Articles by Janjic, N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2008, p. 2639-2643, Vol. 52, No. 7
0066-4804/08/$08.00+0     doi:10.1128/AAC.00310-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Prevalence of Serotype 19A Streptococcus pneumoniae among Isolates from U.S. Children in 2005-2006 and Activity of Faropenem

Replidyne, Inc., Louisville, Colorado 80027,¹ Department of Pathology, Case Western Reserve University, and University Hospitals, Case Medical Center, Cleveland, Ohio 44106,² Clinical Microbiology Institute, Wilsonville, Oregon 97070,³ Replidyne, Inc., Milford, Connecticut 06460⁴

Received 6 March 2008/ Returned for modification 3 April 2008/ Accepted 18 April 2008

Of 393 isolates of Streptococcus pneumoniae from U.S. children collected in 2005-2006, nonvaccine serotypes accounted for 89.1%, with serotype 19A the most prevalent, representing 30.5% of all isolates. The MIC₉₀ of faropenem against serotype 19A isolates was 1 µg/ml, compared to 8 µg/ml against amoxicillin/clavulanate, cefdinir, cefuroxime axetil, and azithromycin.

Published ahead of print on 28 April 2008.